Clarithromycin as Immunomodulator for the Management of Sepsis
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The herein protocol is based on the results of one former clinical trial conducted by our
study group showing the considerable efficacy of intravenously administered clarithromycin as
an adjuvant to antimicrobial chemotherapy for patients with sepsis, septic shock and
respiratory failure in the field of ventilator-associated pneumonia. The proposed clinical
trial is based on the need to generalize the application of intravenous clarithromycin in the
total of admitted septic patients irrespective of the underlying cause of sepsis.